<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Traumatology and Orthopedics of Russia</journal-id><journal-title-group><journal-title xml:lang="en">Traumatology and Orthopedics of Russia</journal-title><trans-title-group xml:lang="ru"><trans-title>Травматология и ортопедия России</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2311-2905</issn><issn publication-format="electronic">2542-0933</issn><publisher><publisher-name xml:lang="en">Vreden National Medical Research Center of Traumatology and Orthopedics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1707</article-id><article-id pub-id-type="doi">10.17816/2311-2905-1707</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>Reviews</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Osteonecrosis in Patients Recovering from COVID-19: Mechanisms, Diagnosis, and Treatment at Early-Stage Disease (Review)</article-title><trans-title-group xml:lang="ru"><trans-title>Остеонекроз у пациентов, перенесших COVID-19: механизмы развития, диагностика, лечение на ранних стадиях (обзор литературы)</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2789-6172</contrib-id><name-alternatives><name xml:lang="en"><surname>Torgashin</surname><given-names>Alexander N.</given-names></name><name xml:lang="ru"><surname>Торгашин</surname><given-names>Александр Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, старший научный сотрудник, врач травматолог-ортопед</p></bio><email>dr.torgashin@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2726-8758</contrib-id><name-alternatives><name xml:lang="en"><surname>Rodionova</surname><given-names>Svetlana S.</given-names></name><name xml:lang="ru"><surname>Родионова</surname><given-names>Светлана Семеновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Scientific and Clinical Center for Osteoporosis</p></bio><bio xml:lang="ru"><p>профессор, доктор медицинских наук, руководитель научно-клинического центра остеопороза, врач травматолог-ортопед</p>
<p> </p></bio><email>rod06@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Traumatology and Orthopedics named after N.N. Priorov</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр травматологии и ортопедии им. Н.Н. Приорова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2022-02-22" publication-format="electronic"><day>22</day><month>02</month><year>2022</year></pub-date><pub-date date-type="pub" iso-8601-date="2022-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2022</year></pub-date><volume>28</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>128</fpage><lpage>137</lpage><history><date date-type="received" iso-8601-date="2021-11-23"><day>23</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-02-15"><day>15</day><month>02</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Torgashin A.N., Rodionova S.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Торгашин А.Н., Родионова С.С.</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2022,</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Torgashin A.N., Rodionova S.S.</copyright-holder><copyright-holder xml:lang="ru">Торгашин А.Н., Родионова С.С.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journal.rniito.org/jour/article/view/1707">https://journal.rniito.org/jour/article/view/1707</self-uri><abstract xml:lang="en"><p><bold><italic>Background.</italic></bold> Aseptic bone necrosis (osteonecrosis), as a consequence of the ongoing coronavirus disease-2019 (COVID-19) pandemic, is increasingly becoming the cause of severe pain syndrome in the hip, knee, and shoulder joints with disruption of their function. The discussion of the pathogenesis of post-COVID-19 osteonecrosis, possibility of its diagnosis, and treatment at early stages continue. As COVID-19 affects young and able-bodied people, the diagnosis and treatment of this form of aseptic necrosis at early stages have great social and economic importance.</p> <p><bold><italic>Methods.</italic></bold> The literature search was conducted in the databases of eLIBRARY, PubMed, and Scopus. The search depth was 10 years. Selected publications were related to the early diagnosis and treatment of aseptic necrosis following COVID-19.</p> <p><bold><italic>Results. </italic></bold>The form of osteonecrosis that developed after COVID-19 should now be classified according to ICD-10 as M87.3 (another secondary osteonecrosis). The review provides data on the possible mechanisms of osteonecrosis development in patients who had COVID-19, explains the role of MRI for the early detection of the pathology, provides the results of treatment that can influence both pathogenesis mechanisms, and leads to disease regression if treatment was initiated at an early stage.</p> <p><bold><italic>Conclusions. </italic></bold>Improving the doctors’ awareness about the pathogenesis, diagnostic methods, and treatment of early disease stages will reduce the risk of developing an advanced stage of aseptic necrosis post-COVID-19, slow down the progression of the pathology, and delay or even prevent the need for joint replacement. Our concern is based on the continuation of the pandemic, the observed fact of the dramatic increase in the frequency of aseptic necrosis post-COVID-19, and the number of total arthroplasties in young and middle-aged people for aseptic necrosis of the femoral head.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Актуальность. </italic></bold>Асептический некроз костей (остеонекроз) как следствие перенесенного COVID-19 в условиях продолжающейся пандемии все чаще становится причиной выраженного болевого синдрома в области крупных суставов с нарушением их функции. Продолжается обсуждение патогенеза постковидного остеонекроза, возможности его выявления и лечения на ранних стадиях. Учитывая масштаб распространенности инфекции COVID-19 среди лиц молодого и трудоспособного возраста, выявление и лечение этой формы асептического некроза на ранних стадиях имеет важное социальное и экономическое значение.</p> <p><bold><italic>Материал и методы.</italic></bold> Поиск литературы проведен в базах данных eLIBRARY, PubMed, Scopus. Глубина поиска — 10 лет. Отобраны публикации, касающиеся ранней диагностики и лечения асептического некроза после перенесенного COVID-19.</p> <p><bold><italic>Результаты. </italic></bold>Форму остеонекроза, развившегося после перенесенного COVID-19, в настоящее время следует классифицировать по МКБ-10 как M87.3 – другой вторичный остеонекроз. В обзоре приводятся данные о возможных механизмах развития остеонекроза у пациентов, перенесших СОVID-19, обосновывается необходимость выполнения МРТ для раннего выявления патологии, приводятся результаты лечения, способного оказывать влияние на оба механизма патогенеза и привести к обратному развитию процесса при условии начала лечения на ранней стадии заболевания.</p> <p><bold><italic>Заключение.</italic></bold> Повышение осведомленности врачей о патогенезе, методах диагностики и лечения ранних стадий позволит снизить риск развития запущенной стадии асептического некроза после перенесенного COVID-19, замедлит прогрессирование патологического процесса, отсрочит или даже предотвратит необходимость эндопротезирования суставов. Наша озабоченность основывается на продолжении пандемии и резко возросшей частоте асептического некроза после COVID-19, с одной стороны, и операций эндопротезирования у лиц молодого и среднего возраста по поводу асептического некроза головки бедренной кости, с другой стороны.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>aseptic necrosis after COVID-19</kwd><kwd>osteonecrosis</kwd><kwd>COVID-19</kwd><kwd>glucocorticoids</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>асептический некроз суставов после COVID-19</kwd><kwd>остеонекроз</kwd><kwd>СОVID-19</kwd><kwd>глюкокортикоиды</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>WHO coronavirus disease (COVID-19) Dashboard. Available from: https://covid19.who.int/table.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Leung T.Y.M., Chan A.Y.L., Chan E.W., Chan V.K.Y., Chui C.S.L., Cowling B.J. et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect. 2020;9(1):2190-2199. doi: 10.1080/22221751.2020.1825914.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mahase E. Covid-19: What do we know about «long covid»? BMJ. 2020;370:m2815. doi: 10.1136/bmj.m2815.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Agarwala S.R., Vijayvargiya M., Pandey P. Avascular necrosis as a part of ‘long COVID-19’. BMJ Case Rep. 2021;14(7):e242101. doi: 10.1136/bcr-2021-242101.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Griffith J.F. Musculoskeletal complications of severe acute respiratory syndrome. Semin Musculoskelet Radiol. 2011;15(5):554-560. doi: 10.1055/s-0031-1293500.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hong N., Du X.K. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol. 2004;59(7):602-608. doi: 10.1016/j.crad.2003.12.008.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lv H., de Vlas S.J., Liu W., Wang T.B., Cao Z.Y., Li C.P. et al. Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study. Trop Med Int Health. 2009;14 Suppl 1(Suppl 1):79-84. doi: 10.1111/j.1365-3156.2008.02187.x.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sardu C., Gambardella J., Morelli M.B., Wang X., Marfella R., Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020;9(5):1417. doi: 10.3390/jcm9051417.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Escher R., Breakey N., Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62. doi: 10.1016/j.thromres.2020.04.014.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Gralinski L.E., Ferris M.T., Aylor D.L., Whitmore A.C., Green R., Frieman M.B. et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015;11(10): e1005504. doi: 10.1371/journal.pgen.1005504.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Oxley T.J., Mocco J., Majidi S., Kellner C.P., Shoirah H., Singh I.P. et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382(20):e60. doi: 10.1056/NEJMc2009787.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539. doi: 10.1007/s00281-017-0629-x.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Van Reeth K., Van Gucht S., Pensaert M. Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune pigs. Viral Immunol. 2002;15(4):583-594. doi: 10.1089/088282402320914520.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Nie S., Han S., Ouyang H., Zhang Z. Coronavirus Disease 2019-related dyspnea cases difficult to interpret using chest computed tomography. Respir Med. 2020;167:105951. doi: 10.1016/j.rmed.2020.105951.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Полякова Ю.В., Папичев Е.В., Ахвердян Ю.Р., Сивордова Л.Е., Заводовский Б.В. Новая коронавирусная инфекция – прямое и косвенное влияние на пациентов с болезнями костно-мышечной системы и соединительной ткани. Современные проблемы науки и образования. 2021;(6). Режим доступа: https://science-education.ru/ru/article/view?id=31342. Polyakova Yu.V., Papichev E.V., Akhverdyan Y.R., Sivordova L.E., Zavodovskiy B.V. [New coronavirus infection - direct and indirect impact on patients with diseases of the musculoskeletal system and connective tissue]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2021;(6). (In Russian). Available from: https://science-education.ru/ru/article/view?id=31342.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Муштин Н.Е., Цед А.Н., Дулаев А.К., Ильющенко К.Г., Шмелев А.В. Влияние новой короновирусной инфекции COVID-19 на развитие остеонекроза. В кн.: Медицинская помощь при травмах, новое в организации и технологиях, роль национальной общественной профессиональной организации травматологов в системе здравоохранения РФ. Санкт-Петербург; 2021. c. 98-99. Mushtin N.E., Tsed A.N., Dulaev A.K., Ilyushchenko K.G., Shmelev A.V. [A variant of the new coronovirus infection Covid-19 for the development of osteonecrosis]. In: Meditsinskaya pomoshch’ pri travmakh, novoe v organizatsii i tekhnologiyakh, rol’ natsional’noi obshchestvennoi professional’noi organizatsii travmatologov v sisteme zdravookhraneniya RF: sbornik tezisov [Medical care for injuries, new organization and technology, the role of the national professional organization of traumatologists in the healthcare system of the Russian Federation]. St. Petersburg: 2021. p. 98-99. (In Russian).</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Strehl C., Ehlers L., Gaber T., Buttgereit F. Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System. Front Immunol. 2019;10:1744. doi: 10.3389/fimmu.2019.01744.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Russell B., Moss C., Rigg A., Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023. doi: 10.3332/ecancer.2020.1023.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Russell B., Moss C., George G., Santaolalla A., Cope A., Papa S. et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. doi: 10.3332/ecancer.2020.1022.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Arabi Y.M., Fowler R., Hayden F.G. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315-328. doi: 10.1007/s00134-020-05943-5.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lau E.M., Chan F.W., Hui D.S., Wu A.K., Leung P.C. Reduced bone mineral density in male Severe Acute Respiratory Syndrome (SARS) patients in Hong Kong. Bone. 2005;37(3):420-424. doi: 10.1016/j.bone.2005.04.018.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Yang X., Yu Y., Xu J., Shu H., Xia J. Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Villar J., Ferrando C., Martínez D., Ambrós A., Muñoz T., Soler J.A. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276. doi: 10.1016/S2213-2600(19)30417-5.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>RECOVERY Collaborative Group, Horby P., Lim W.Sh., Emberson J.R., Mafham M., Bell J.L. et al. Dexamethasone in Hospitalized Patients with COVID-19 — Preliminary Report. N Engl J Med. 2021; 384(8):693-704. doi: 10.1056/NEJMoa2021436.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Powell C., Chang C., Naguwa S.M., Cheema G., Gershwin M.E. Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev. 2010;9(11):721-743. doi: 10.1016/j.autrev.2010.06.007.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Koromila T., Baniwal S.K., Song Y.S., Martin A., Xiong J., Frenkel B. Glucocorticoids antagonize RUNX2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells. J Cell Biochem. 2014;115(1):27-33. doi: 10.1002/jcb.24646.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Matthews B. Involvement of the osteoblast in Paget’s disease of bone. Medicine. 2009. Available from: https://www.semanticscholar.org/paper/Involvement-of-the-osteoblast-in-Paget%27s-disease-of-Matthews/c20b73cf3d1e1d6ed15801a3ac5e230459fcf1b7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>O’Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A. et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-1841. doi: 10.1210/en.2003-0990.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Koo K.H., Kim R., Kim Y.S., Ahn I.O., Cho S.H., Song H.R. et al. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol. 2002;21(4):299-303. doi: 10.1007/s100670200078.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kerachian M.A., Séguin C., Harvey E.J. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009;114(3-5):121-128. doi: 10.1016/j.jsbmb.2009.02.007.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Fu L., Liu H., Lei W. MiR-596 inhibits osteoblastic differentiation and cell proliferation by targeting Smad3 in steroid-induced osteonecrosis of femoral head. J Orthop Surg Res. 2020;15(1):173. doi: 10.1186/s13018-020-01688-5.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Yamasaki K., Nakasa T., Miyaki S., Yamasaki T., Yasunaga Y., Ochi M. Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res. 2012;30(8):1263-1270. doi: 10.1002/jor.22079.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jia J., Feng X., Xu W., Yang S., Zhang Q., Liu X. et al. MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis. Exp Mol Med. 2014;46(7):e107. doi: 10.1038/emm.2014.43.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Weinstein R.S., Wan C., Liu Q., Wang Y., Almeida M., O’Brien C.A. et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9(2):147-161. doi: 10.1111/j.1474-9726.2009.00545.x.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Xu Y., Chen Y., Tang X. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. Glob Health Med. 2020;2(2):66-72. doi: 10.35772/ghm.2020.01015.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Zheng Y., Xiong C., Liu Y., Qian X., Tang Y., Liu L. et al. Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. Pharmacol Res. 2020;157:104821. doi: 10.1016/j.phrs.2020.104821.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Zhao R., Wang H., Wang X., Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2017;28(3):1027-1034. doi: 10.1007/s00198-016-3824-z.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Shen J., Liang B.L., Zeng Q.S., Chen J.Y., Liu Q.Y., Chen R.C. et al. [Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou]. Zhonghua Yi Xue Za Zhi. 2004;84(21):1814-1817. (In Chinese).</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Motomura G., Yamamoto T., Irisa T., Miyanishi K., Nishida K., Iwamoto Y. Dose effects of corticosteroids on the development of osteonecrosis in rabbits. J Rheumatol. 2008;35(12):2395-2399. doi: 10.3899/jrheum.080324.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Marsh J.C., Zomas A., Hows J.M., Chapple M., Gordon-Smith E.C. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Br J Haematol. 1993;84(4):731-735. doi: 10.1111/j.1365-2141.1993.tb03153.x.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Mont M.A., Pivec R., Banerjee S., Issa K., Elmallah R.K., Jones L.C. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015;30(9):1506-1512.e5. doi: 10.1016/j.arth.2015.03.036.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Guo K.J., Zhao F.C., Guo Y., Li F.L., Zhu L., Zheng W. The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study. Bone Joint J. 2014;96-B(2):259-262. doi: 10.1302/0301-620X.96B2.31935.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Rademaker J., Dobro J.S., Solomon G. Osteonecrosis and human immunodeficiency virus infection. J Rheumatol. 1997;24(3):601-604.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Chan M.H., Chan P.K., Griffith J.F., Chan I.H., Lit L.C., Wong C.K. et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology. 2006;38(3):229-235. doi: 10.1080/00313020600696231.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Richards R.N. Short-term Corticosteroids and Avascular Necrosis: Medical and Legal Realities. Cutis. 2007;80(4):343-348.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Zhao F.C., Li Z.R., Guo K.J. Clinical analysis of osteonecrosis of the femoral head induced by steroids. Orthop Surg. 2012;4(1):28-34. doi: 10.1111/j.1757-7861.2011.00163.x.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Mirzai R., Chang C., Greenspan A., Gershwin M.E. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma. 1999;36(1):77-95. doi: 10.3109/02770909909065152.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Zhao F.C., Hu H.X., Zheng X., Cang D.W., Liu X., Zhang J.Z. et al. Clinical analysis of 23 cases of steroid-associated osteonecrosis of the femoral head with normal initial magnetic resonance imaging presentation. Medicine (Baltimore). 2017;96(49):e8834. doi: 10.1097/MD.0000000000008834.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Sun W., Li Z., Shi Z., Wang B., Gao F., Yang Y. et al. Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms. Eur J Orthop Surg Traumatol. 2014;24(4):525-529. doi: 10.1007/s00590-013-1223-0.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Wei B., Wei W. Identification of aberrantly expressed of serum microRNAs in patients with hormone-induced non-traumatic osteonecrosis of the femoral head. Biomed Pharmacother. 2015;75:191-195. doi: 10.1016/j.biopha.2015.07.016.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Hsu S.L., Wang C.J., Lee M.S., Chan Y.S., Huang C.C., Yang K.D. Cocktail therapy for femoral head necrosis of the hip. Arch Orthop Trauma Surg. 2010;130(1):23-29. doi: 10.1007/s00402-009-0918-5.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Wong T., Wang C.J., Hsu S.L., Chou W.Y., Lin P.C., Huang C.C. Cocktail therapy for hip necrosis in SARS patients. Chang Gung Med J. 2008;31(6):546-553.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Wang W., Zhang N., Guo W., Gao F. Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteen year follow-up. Int Orthop. 2018;42(7):1551-1556. doi: 10.1007/s00264-018-3907-x.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Klumpp R., Trevisan C. Aseptic osteonecrosis of the hip in the adult: current evidence on conservative treatment. Clin Cases Miner Bone Metab. 2015;12(Suppl 1):39-42. doi: 10.11138/ccmbm/2015.12.3s.039.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Agarwala S., Banavali S.D., Vijayvargiya M. Bisphosphonate Combination Therapy in the Management of Postchemotherapy Avascular Necrosis of the Femoral Head in Adolescents and Young Adults: A Retrospective Study From India. J Glob Oncol. 2018;4: 1-11. doi: 10.1200/JGO.17.00083.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Ramachandran M., Ward K., Brown R.R., Munns C.F., Cowell C.T., Little D.G. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am. 2007;89(8):1727-1734. doi: 10.2106/JBJS.F.00964.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Karim A.R., Cherian J.J., Jauregui J.J., Pierce T., Mont M.A. Osteonecrosis of the knee: review. Ann Transl Med. 2015;3(1):6. doi: 10.3978/j.issn.2305-5839.2014.11.13.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Zywiel M.G., McGrath M.S., Seyler T.M., Marker D.R., Bonutti P.M., Mont M.A. Osteonecrosis of the knee: a review of three disorders. Orthop Clin North Am. 2009;40(2):193-211. doi: 10.1016/j.ocl.2008.10.010.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Hong Y.C., Luo R.B., Lin T., Zhong H.M., Shi J.B. Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. Biomed Res Int. 2014;2014:716538. doi: 10.1155/2014/716538.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Cross M., Macara M., Little E., Chan M., Little D., Buchbinder R. et al. Efficacy of zoledronate in treating osteonecrosis of femoral head: a randomized controlled trial Abstracts. Osteoarthritis and Cartilage. 2018;26(Suppl 1):S309-S310. doi: 10.1016/j.joca.2018.02.622.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Agarwala S., Vijayvargiya M. Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip. Ann Rehabil Med. 2019;43(3):314-320. doi: 10.5535/arm.2019.43.3.314.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Rolvien T., Schmidt T., Butscheidt S., Amling M., Barvencik F. Denosumab is effective in the treatment of bone marrow oedema syndrome. Injury. 2017;48(4):874-879. doi: 10.1016/j.injury.2017.02.020.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Родионова С.С., Еловой-Вронский А.А., Бернакевич А.И. Альфакальцидол или колекальциферол в комбинации с ибандроновой кислотой при лечении постменопаузального системного остеопороза. Остеопороз и остеопатии. 2014;17(1):21-24. Rodionova S.S., Elovoy-Vronskiy A.A., Bernakevich A.I. [Alfacalcidol or cholecalciferol in combination with ibandronic acid in the treatment of postmenopausal systemic osteoporosis]. Osteoporoz i osteopatii [Osteoporosis and Bone Diseases]. 2014;17(1):21-24. (In Russian).</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L. et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988. doi: 10.3390/nu12040988.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Annweiler C., Hanotte B., Grandin de l’Eprevier C., Sabatier J.M., Lafaie L., Célarier T. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J Steroid Biochem Mol Biol. 2020;204:105771. doi: 10.1016/j.jsbmb.2020.105771.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Kakodkar P., Kaka N., Baig M.N. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). Cureus. 2020;12(4):e7560. doi: 10.7759/cureus.7560.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Gangji V., Soyfoo M.S., Heuschling A., Afzali V., Moreno-Reyes R., Rasschaert J. et al. Non traumatic osteonecrosis of the femoral head is associated with low bone mass. Bone. 2018;107:88-92. doi: 10.1016/j.bone.2017.11.005.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., Дзеранова Л.К., Драпкина О.М. и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4-47. doi: 10.14341/osteo12930. Belaya Z.E., Belova K.Yu., Biryukova E.V., Dedov I.I., Dzeranova L.K., Drapkina O.M. et al. [Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis]. Osteoporoz i osteopatii [Osteoporosis and Bone Diseases]. 2021;24(2):4-47. (In Russian). doi: 10.14341/osteo12930.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Торгашин А.Н. , Родионова С.С., А.А. Шумский А.А., Макаров М.А., Торгашина А.В., Ахтямов И.Ф. и др. Лечение асептического некроза головки бедренной кости. Клинические рекомендации. Научно-практическая ревматология. 2020;58(6):637-645. Torgashin A.N., Rodionova S.S., Shumsky A.A., Makarov M.A., Torgashina A.V., Akhtyamov I.F. et al. [Treatment of aseptic necrosis of the femoral head. Clinical guidelines]. Nauchno-prakticheskaya revmatologiya [Rheumatology Science and Practice]. 2020;58(6):637-645. (In Russian).</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Jäger M., Zilkens C., Bittersohl B., Matheney T., Kozina G., Blondin D. et al. Efficiency of iloprost treatment for osseous malperfusion. Int Orthop. 2011;35(5):761-765. doi: 10.1007/s00264-010-0998-4.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Claßen T., Becker A., Landgraeber S., Haversath M., Li X., Zilkens C. et al. Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis. Orthop Rev (Pavia). 2016;8(1):6150. doi: 10.4081/or.2016.6150.</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Glueck C.J., Freiberg R.A., Sieve L., Wang P. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res. 2005;(435):164-170. doi: 10.1097/01.blo.0000157539.67567.03.</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Billett H.H., Reyes-Gil M., Szymanski J., Ikemura K., Stahl L.R., Lo Y. et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thromb Haemost. 2020;120(12):1691-1699. doi: 10.1055/s-0040-1720978.</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Trancik T., Lunceford E., Strum D. The effect of electrical stimulation on osteonecrosis of the femoral head. Clin Orthop Relat Res. 1990;(256):120-124.</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Rajagopal M., Balch Samora J., Ellis T.J. Efficacy of core decompression as treatment for osteonecrosis of the hip: a systematic review. Hip Int. 2012;22(5):489-493. doi: 10.5301/HIP.2012.9748.</mixed-citation></ref></ref-list></back></article>
